Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2020, with a specific transaction date of September 7, 2020. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of a specific equity transaction.
| Metric | Value |
|---|---|
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Type | Award of Ordinary Shares under the 2015 Share Value Plan |
| Volume | 10,050 shares |
| Price per Share | £14.96 |
| Transaction Date | September 7, 2020 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It discloses a single, isolated equity award event.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is a regulatory compliance filing for a specific share award.
Key Facts for Investor Verification
- The transaction involves an award of 10,050 ordinary shares to Mrs. V A Whyte, SVP & Company Secretary.
- The award was made under the Company's 2015 Share Value Plan at a price of £14.96 per share.
- This filing does not provide any quarterly or annual financial results; investors should refer to Form 20-F or other periodic reports for financial performance.